CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents at carrying value	$ 89,831,744	$ 18,559,130
Short-term investments	83,292,883	78,912,297
Receivables		273,044
Prepaid expenses	1,259,420	751,255
Other assets	172,390	77,077
Total current assets	174,556,437	98,572,803
Property and equipment, net	1,942,852	2,182,399
Other noncurrent assets	178,941	7,067
Total assets	176,678,230	100,762,269
Current liabilities:
Accounts payable	1,414,607	376,394
Accrued wages and benefits	1,120,772	2,533,133
Accrued clinical trial expenses	1,007,396	689,985
Accrued expenses and other liabilities	1,070,302	946,668
Total current liabilities	4,613,077	4,546,180
Deferred revenue, net of current portion	363,266	731,944
Total liabilities	4,976,343	5,278,124
Stockholders’ equity:
Common stock: $0.001 par value, 100,000,000 shares authorized; 48,203,529 and 69,427,773 shares issued and outstanding at December 31, 2017 and March 31, 2018	69,428	48,204
Additional paid-in capital	488,929,377	404,454,909
Accumulated other comprehensive (loss) income	(79,143)	(64,433)
Retained deficit	(317,217,775)	(308,954,535)
Total stockholders’ equity	171,701,887	95,484,145
Total liabilities and stockholders’ equity	$ 176,678,230	$ 100,762,269